Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TS-121 as adjunctive treatment for major depressive disorder was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• TS-121

Snippet

Sponsor: Taisho Pharmaceutical R&D Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2019-12-09